Hyperion Defi Inc (HYPD) Stock Price, Quote & News

Company Profile

Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in Chin...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 289 1117

Website: hyperiondefi.com

Address:

295 Madison Avenue, Suite 2400, New York, United States

Mike827 Dec. 25 at 4:07 AM

$HYPD stock price is doing nothing different then when it was under previous management who was peddling a scam eyedroper 🤷🏿‍♀️🤷🏿‍♀️🤷🏿‍♀️🤷🏿‍♀️🤷🏿‍♀️🤷🏿‍♀️🤷🏿‍♀️

0 · Reply

Mike827 Dec. 25 at 3:59 AM

$HYPD do shareholders potentially get like a dividend or something? i thouget I remember something about the current ceo saying something about when the treasury started doing it’s thing shareholders would receive a piece of the pie?????

0 · Reply

Jwa68 Dec. 24 at 8:18 PM

$HYPD Nice to see the new initiation and $7.75 target. I like the analyst James personally and professionally.

0 · Reply

PhishTourFunds Dec. 24 at 3:34 PM

$HYPD 👀

0 · Reply

JarvisFlow Dec. 24 at 12:31 PM

Chardan Capital updates rating for Hyperion DeFi ( $HYPD ) to Buy, target set at 7.75.

0 · Reply

BlockTradeBoss Dec. 24 at 10:11 AM

$HYPD The longer-term setup revolves around whether timelines compress uncertainty rather than extend speculation. Inconsistent delivery may prolong volatility.

0 · Reply

BullTradeFinder Dec. 23 at 7:36 PM

$HYPD Developing Long-Term Value in Eye Health They are building eye-health IP and licensing potential while trading at discounted levels. Improving balance sheet trends and stabilizing price action make it a measured value opportunity worth watching. -Q4 revenue guide: $475K–$515K Growth of 30%+ Quarter over Quarter. -Cash flow expected to turn positive in 2026 Communicated-Disclaimer https://stockresearchtoday.com/brizy-12569/

0 · Reply

jcooptechit Dec. 23 at 5:20 PM

$HYPD CRYPTO PLAY IS FIRING ON ALL CYLINDERS Hyperion DeFi recently posted record Q3 profits: $6.6M net income and $7.95M EBITDA. And NAV sits at $74.5M with $77.8M in HYPE holdings. 🔸 Staked $HYPE.X jumped from 8.25M → 13.21M tokens in one month. 🔸 Q4 revenue guide: $475K–$515K (+31–43% QoQ) 🔸 Cash flow expected to turn positive in 2026 Profitable DeFi. Growing treasury. Compounding yield. Communicated - Disclaimer: https://chartingdaily.com/creative-design-platform

0 · Reply

Mike827 Dec. 23 at 4:40 PM

$HYPD we need a business update

0 · Reply

TheRealShortSqueezy Dec. 23 at 3:44 PM

$HYPD : A Public Gateway to DeFi 🔗 Hyperion DeFi is building a DeFi-focused digital asset treasury, offering public market exposure to on chain ecosystems. Why HYPE coin? HYPD chose HYPE because it sits at the center of the Hyperliquid ecosystem, one of the most active on-chain trading platforms. As usage and volume grow, HYPE benefits directly, making it a strategic asset rather than a passive crypto holding. Latest news: ➡️Received the Kinetiq airdrop ➡️Announced a partnership with Native Markets ➡️Purchased 150,000 additional HYPE tokens ➡️Director Michael S. Geltzeiler bought 30,000 shares at $3.00 in an open-market insider purchase ➡️ Cantor Fitzgerald initiated coverage Overweight with a $4 price target HYPD isn’t watching DeFi from the sidelines, it’s building exposure from the inside. Communicated Disclaimer: https://stockresearchtoday.com/brizy-12569/ Sector Peers: $MSTR $MARA $XXI $CEPO

0 · Reply

Hyperion DeFi, Inc. (HYPD) Q3 2025 Earnings Call Transcript

Sep 29, 2025, 8:00 AM EDT - 3 months ago

Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

Sep 27, 2025, 7:30 AM EDT - 3 months ago

Many crypto-treasury companies are trading for less than what their digital assets are worth. Is this a bargain or a big red flag?

ALTS MARA MSTR

Sep 25, 2025, 8:00 AM EDT - 3 months ago

Hyperion DeFi Adds $10M in HYPE to its Treasury Holdings

Sep 16, 2025, 8:00 AM EDT - 3 months ago

Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo

Aug 14, 2025, 10:16 AM EDT - 4 months ago

Kinetiq Announces iHYPE Launch with Hyperion DeFi as First Institutional Depositor

Aug 13, 2025, 4:01 PM EDT - 4 months ago

Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 8, 2025, 4:05 PM EDT - 4 months ago

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

Jul 28, 2025, 8:00 AM EDT - 5 months ago

Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy

Jul 17, 2025, 8:00 AM EDT - 5 months ago

Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evolution from Eyenovia and the Future of On-Chain Finance on July 29, 2025

Jul 14, 2025, 4:05 PM EDT - 5 months ago

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings

Jun 18, 2025, 2:04 PM EDT - 6 months ago

Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings

KIDZ LGHL VVPR

Jun 18, 2025, 8:32 AM EDT - 6 months ago

Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group

Jun 17, 2025, 3:54 PM EDT - 6 months ago

Eyenovia Surges on Crypto Announcement

Jun 17, 2025, 2:55 PM EDT - 6 months ago

Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy

May 19, 2025, 5:30 PM EDT - 7 months ago

Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results

Apr 10, 2025, 7:00 AM EDT - 9 months ago

Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

Mar 20, 2025, 7:00 AM EDT - 9 months ago

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

Feb 26, 2025, 7:00 AM EST - 10 months ago

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

Feb 24, 2025, 7:00 AM EST - 10 months ago

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives

Feb 5, 2025, 7:00 AM EST - 11 months ago

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

Jan 28, 2025, 4:05 PM EST - 11 months ago

Eyenovia Announces 1-for-80 Reverse Stock Split

Jan 15, 2025, 7:00 AM EST - 1 year ago

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

Jan 6, 2025, 7:00 AM EST - 1 year ago

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

Dec 6, 2024, 8:00 AM EST - 1 year ago

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering

Nov 22, 2024, 7:00 AM EST - 1 year ago

Eyenovia Provides Update on Restructuring Efforts

Nov 15, 2024, 1:15 PM EST - 1 year ago

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

Nov 15, 2024, 7:07 AM EST - 1 year ago

Eyenovia to discontinue late-stage study for eye drug

Nov 15, 2024, 7:00 AM EST - 1 year ago

Eyenovia Provides Update on Phase 3 CHAPERONE Study

Nov 12, 2024, 10:42 PM EST - 1 year ago

Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 1 year ago

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

Sep 27, 2024, 8:30 AM EDT - 1 year ago

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

Sep 9, 2024, 3:00 AM EDT - 1 year ago

Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

Aug 23, 2024, 11:42 AM EDT - 1 year ago

Eyenovia Announces Closing of Public Offering

Aug 22, 2024, 2:20 PM EDT - 1 year ago

Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?

Aug 21, 2024, 9:29 AM EDT - 1 year ago

Eyenovia Announces Pricing of $5.14 Million Public Offering

Aug 20, 2024, 5:09 PM EDT - 1 year ago

Eyenovia, Inc. Announces Proposed Public Offering

Aug 12, 2024, 11:07 PM EDT - 1 year ago

Eyenovia, Inc. (EYEN) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

Aug 7, 2024, 5:11 PM EDT - 1 year ago

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

Jul 1, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

NBY

Mike827 Dec. 25 at 4:07 AM

0 · Reply

Mike827 Dec. 25 at 3:59 AM

0 · Reply

Jwa68 Dec. 24 at 8:18 PM

$HYPD Nice to see the new initiation and $7.75 target. I like the analyst James personally and professionally.

0 · Reply

PhishTourFunds Dec. 24 at 3:34 PM

$HYPD 👀

0 · Reply

JarvisFlow Dec. 24 at 12:31 PM

Chardan Capital updates rating for Hyperion DeFi ( $HYPD ) to Buy, target set at 7.75.

0 · Reply

BlockTradeBoss Dec. 24 at 10:11 AM

$HYPD The longer-term setup revolves around whether timelines compress uncertainty rather than extend speculation. Inconsistent delivery may prolong volatility.

0 · Reply

BullTradeFinder Dec. 23 at 7:36 PM

0 · Reply

jcooptechit Dec. 23 at 5:20 PM

0 · Reply

Mike827 Dec. 23 at 4:40 PM

$HYPD we need a business update

0 · Reply

TheRealShortSqueezy Dec. 23 at 3:44 PM

0 · Reply

The_Titan_Traders Dec. 23 at 3:35 PM

$HYPD — Ultra Bullish Thesis • Profitable Turnaround • Recent quarter showed real profitability (multi-million net income & EBITDA) • Major shift from legacy model → DeFi / crypto-infrastructure revenue • DeFi Exposure (Not Hype Only) • Validator + staking-style revenue model • Strategic crypto asset accumulation (token treasury angle) • Leverage to DeFi adoption + crypto market expansion • Institutional + Insider Confidence • Institutions increasing positions sharply • Insider buying in open market → confidence at current prices • Cantor Fitzgerald initiated coverage with Overweight rating • High Short Interest = Fuel • ~25%+ short interest • Any sustained upside = short squeeze risk • Thin float amplifies moves • Technical Setup • Holding key $3–4 base after selloff • Break & hold above $4 can trigger a move Communicated-Disclaimer: https://stockresearchtoday.com/innovative-recycling/

1 · Reply

JTE_Theta Dec. 23 at 3:25 PM

$HYPD High Short Interest + Tight Float Hyperion DeFi offers public market access to the DeFi ecosystem through a strategic HYPE token treasury ! no wallets or on chain trading required. Why HYPD is in my watchlist ⬇️ •Direct DeFi exposure via a public stock • Early stage leveraged play on Hyperliquid growth •NASDAQ listed, early stage opportunity CommunicatedDisclaimer: http://stockresearchtoday.com/brizy-12569/

0 · Reply

Jwa68 Dec. 23 at 2:27 PM

$HYPD Great commentary from CEO Hyunsu Jung. https://cointelegraph.com/news/dex-adoption-hip-3-hype-200-hyperliquid

0 · Reply

OfficialStocktwitsUser Dec. 23 at 3:25 AM

$HYPD RSI: 52.79, MACD: -0.5312 Vol: 0.43, MA20: 3.72, MA50: 5.31 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MadMaverick Dec. 23 at 2:02 AM

$HYPD continues on its march up! Another insider purchase, third in recent days. Team continues to put their money where their mouth is. KEY FACTORS: 🔹Actively generating revenue through on-chain staking and its co-branded validator with Kinetiq. 🔹Providing a regulated, Nasdaq-listed vehicle for investors to gain exposure to decentralized finance. For more details about the growth potential: 👇🏼 Communicated Disclaimer - https://chartingdaily.com/creative-design-platform

0 · Reply

Mike827 Dec. 22 at 8:34 PM

$HYPD so they should be accumulating massive amounts of hype tokens now.

0 · Reply

whjo Dec. 22 at 2:54 PM

$HYPD go on buying!

0 · Reply

Jwa68 Dec. 22 at 2:14 PM

$HYPD Another insider purchase, third in recent days. Team continues to put their money where their mouth is. All DAT's arent equal. Best in class management and model at Hyperion DeFi in my opinion.

0 · Reply

AZOZ Dec. 22 at 12:09 PM

$HYPD Insider activity!

0 · Reply

Jwa68 Dec. 20 at 5:40 AM

$HYPD More sizeable insider buying. https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-25-123366/tm2533954-3_4seq1.html

0 · Reply

Jwa68 Dec. 20 at 5:38 AM

$HYPD Always nice to see insider biying, putting their own money where their mouth is. https://ir.hyperiondefi.com/sec-filings/all-sec-filings/content/0001104659-25-122897/tm2533954-2_4seq1.html

0 · Reply

Azlvr Dec. 19 at 6:27 PM

$HYPD Review Alejos here. 😑 https://www.trustpilot.com/review/www.jccapitalconsultants.com

0 · Reply

Market Cap	30.65M
Revenue (ttm)	60,000.00
Net Income (ttm)	-49.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-83,033.33%
Debt to Equity Ratio	0.11

Volume	203,900
Avg Vol	384,032
Day's Range	N/A - N/A
Shares Out	8.17M
Stochastic %K	76%
Beta	2.80
Analysts	Strong Sell
Price Target	$4.00